First Blood-Based Lung Cancer EGFR Test Gets FDA Green Light
This article was originally published in The Pink Sheet Daily
Roche's cobas EGFR Mutation Test v2 liquid biopsy test is approved to detect genetic mutations linked to drug response in patients with non-small cell lung cancer treated with Tarceva.
You may also be interested in...
Roche Molecular Diagnostic's top researcher, Walter Koch, discusses the promise of liquid biopsy following FDA's recent approval of its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.
New cancer companion diagnostic approved. Biotronik’s Ilesto 7 ICD and CRT-D earns FDA approval. More new product announcements.